Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBX7 | O95931 | 1/20 | 0.58 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.58 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.58 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.47 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8607621 | 0.85 | GRIA1 (0.70) | CBX7CDYL2CDYLCDY1; CDY1BDAO | |
| SCHEMBL9049869 | 0.82 | CA12 (0.60) | CA12CA9 | |
| SCHEMBL8046411 | 0.82 | MAT2A (0.52) | CBX7CDYL2CDYLCDY1; CDY1BGRIN2D | |
| SCHEMBL641660 | 0.82 | B3GNT2 (0.47) | CBX7CDYL2CDYLCDY1; CDY1BDAO | |
| SCHEMBL4629626 | 0.82 | B3GNT2 (0.47) | CBX7CDYL2CDYLCDY1; CDY1BPGR | |
| SCHEMBL11703773 | 0.80 | DAO (0.59) | CBX7CDYL2CDYLCDY1; CDY1BDAO | |
| SCHEMBL6910220 | 0.80 | PGR (0.72) | CBX7CDYL2CDYLCDY1; CDY1BDAO | |
| SCHEMBL11708301 | 0.78 | DAO (0.57) | CBX7CDYL2CDYLCDY1; CDY1BDAO | |
| SCHEMBL11506760 | 0.78 | DAO (0.56) | CBX7CDYL2CDYLCDY1; CDY1BDAO | |
| SCHEMBL2255490 | 0.78 | MEN1 (0.62) | DAOLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| WO-2014204859-A2 | BCL6 INHIBITORS AS ANTICANCER AGENTS | MELNICK ARI (US) | 2014-12-24 | — | — | WO | disclosed |
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| CN-101528712-B | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG | 2013-10-30 | — | — | CN | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-2061769-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008025736-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CBX7 4425/4885CDYL2 3970/4885CDYL 4272/4885 |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | CBX7 137/4885CDYL2 225/4885CDYL 224/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CBX7 4425/4885CDYL2 3970/4885CDYL 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.